Organon Abandons Endometriosis Pain Drug Development After Trial Failure
The drug's failure in a proof-of-concept mid-stage study deals a blow to the company's attempt to launch a future driver of revenue, four years after it was spun off from Merck. Another drug acquired by Organon through the up to $954 million Forendo acquisition is still in lab studies.
Organon was testing the drug, OG-6219, in 354 patients aged 18 to 49 who had moderate-to-severe endometriosis-related pain, but results showed no significant improvement compared to a placebo. Improvement in pelvic pain was measured using an 11-point rating scale during the third month of treatment.
Endometriosis is a condition that affects about 190 million women of reproductive age globally, according to the World Health Organization. It occurs when tissue similar to the uterine lining grows outside the uterus, often causing chronic pelvic pain and infertility.
Organon's study was designed to assess whether the drug could meaningfully reduce pelvic pain and patients were randomly chosen to receive one of three pre-decided doses of the drug or a placebo, given orally twice a day.
Current treatments options for endometriosis include hormonal therapies such as birth control pills, progestins, and GnRH modulators such as Myfembree, co-owned by Sumitovant Biopharma and Pfizer, and AbbVie's Orilissa.
Pain is often managed with non-steroidal and anti-inflammatory medicines such as ibuprofen and surgery remains an option for severe cases.
OG-6219 is designed to block an enzyme involved in estrogen production, aiming to reduce pain by lowering levels of estradiol at endometriosis sites without affecting hormone levels throughout the body.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
16 minutes ago
- CBS News
Re-Coding the Future
This content was provided by Acumen Media for Ascendion. This advertiser content was paid for and created by Acumen. Neither CBS News nor CBS News Brand Studio, the brand marketing arm of CBS News, were involved in the creation of this content. Throughout history, new forms of energy have shifted the gears of human progress, profoundly changing how people live and work. Ancient societies started with muscle, moved to animals, then harnessed water, steam and eventually, electricity. Today, AI is emerging as our next energy source, like fire, electricity or steam in past revolutions, to power productivity in the knowledge economy. Horses, steam engines and power plants all still matter of course, but the world is increasingly running on code and software. What some are calling Economy 4.0 is the AI-powered transformation of the knowledge economy, with software reordering how value is created, delivered and scaled. AI is the new power for business, but software is the power grid. It's the axle around which our knowledge economy is starting to turn. Software now shapes how we communicate, manage money, access healthcare, shop, learn, and nearly every other aspect of our modern lives. "Software is one of the key elements of making WellSky successful," said Joel Dolisy, Chief Technology Officer. "There is a lot of people interaction that is all enabled through software. [It] is a big, big important part of how we make that happen." And yet, much of the code that shapes the economy is old enough to collect social security. Nearly $3 trillion worth of global business operations still run on COBOL daily. Despite the increasing criticality of code, the world is still reliant on software that may have been developed by our grandparents. The impact: a chilling effect on disruptive innovation. Vimala Suresh, Vice President, CareSource, said, "If that file doesn't get processed in time, the member can't get the surgery they're eligible for. This could be life-threatening. That's how important software is in healthcare." Software development methods, processes, tools and mindsets from the past are crumbling under the pressure of AI-powered systems and potential. This presents leaders with a once-in-a-career opportunity. That's where Ascendion comes in. The company says it's unleashing intelligent agents that enhance humans as it builds software faster and better. Now, engineers using AAVA, a platform of agents aligned to software development and management, are using AI to deliver better code at half the cost and twice the speed. To unlock the potential value, leaders, Ascendion says IT teams, operations, line-of-business, procurement, finance and the C-suite must lean into new ways of designing, building and managing software. This isn't theory or buzzwords. It's happening now using what Ascendion calls Engineering to the Power of AI (EngineeringAI). This means companies can do more with less, allowing more time for talented humans to create, innovate, imagine and lead. David Park, President, Commercial Bank, Axos Bank, said, "With the speed of development and the reduction of cost through AI, we are able to personalize the banking experience. Hyper-personalization is what's most exciting about financial services and the software evolution we are going through." Marc Andreessen was right when he said, "Software is eating the world." Now, thanks to AI, software engineering is the first course. The data is adding up. Gartner predicts AI software will reach $297 billion by 2027. Researchers are uncovering a double-digit decrease in jobs related to writing and coding. A growing number of early adopter CIOs are already reporting that AI can yield efficiency gains of 20% to 40%. Innovation, growth, savings and transparency aren't new, but this is: AI is moving from the computer science lab to every business. The new power revolution from AI is already starting. The first major disruption where real value is being delivered today comes from how software is being built. AI is changing not just what is built, but how it's built. Every new power revolution—fire, water wheels, steam, electricity and now AI—comes with risks, disruptions and unintended consequences. AI's impact on software engineering will be profound, and it needs to be managed so we advance safely and civilly. In the coming years and decades, AI agents will disrupt countless business processes, consumer experiences and jobs. But today, software engineering is being re-coded by the bot. Business leaders, policy makers and employees can embrace the potential for AI and tame new machines so that value generation tips the scales away from risk, fear and failed projects.
Yahoo
23 minutes ago
- Yahoo
Scientists Just Found Something Very Weird About the Mysterious Object Hurtling Into Our Solar System
As evidence continues to mount that the mysterious object with interstellar origins currently speeding toward the inner solar system at a breakneck speed is a comet, not everybody's convinced quite yet. Harvard astronomer and alien hunter Avi Loeb raised the far-fetched, yet tantalizing possibility that the object, which was first spotted by astronomers earlier this year, could have been sent by an extraterrestrial civilization. While he admitted in a blog post last month that it's most likely that "3I/ATLAS is a completely natural interstellar object, probably a comet," a letter to the editors of the journal Astronomy & Astrophysics has Loeb questioning that conclusion once more. At the heart of the conundrum is the purported comet's tail. The glowing globs of icy particulates conventionally leave a trail of gas and dust in a comet's wake, resulting in their distinctive shape. However, there's a slim chance that 3I/ATLAS may be an outlier. According to the paper, which was authored by an international team of astronomers, 3I/ATLAS "exhibits increasing dust activity and reddening colors during the observation period, with no visible tail detected." The lack of a tail could be "likely due to viewing geometry and low dust production," they posited. The researchers, therefore, called on the astronomy community to continue monitoring the unusual object to glean more "insights into the evolution of interstellar materials under solar radiation." Loeb agreed with the sentiment, arguing in a recent blog post that the "more data we collect, the more difficult it would be for scientists to shove anomalies of 3I/ATLAS under the carpet of traditional thinking." "We are used to finding icy rocks which exhibit familiar cometary tails in the solar system," he added, "but an encounter with objects from interstellar space is a blind date on astronomical scales." To Loeb, it's still too early to definitively conclude that 3I/ATLAS is a comet. To the astronomer, who previously authored a book about the possibility that 'Oumuamua, an interstellar object first observed in 2017, may have been an sent to us by an alien civilization, there's still enough compelling evidence suggesting otherwise. In a follow-up blog post, he pointed out a separate paper, showing that the first images taken of the object by NASA's Hubble Space Telescope showed a nucleus "surrounded by a much larger cloud of dust," and a "diffuse emission ahead of its motion towards the Sun rather than a trailing tail as expected from a typical comet." Loeb has also suggested that 3I/ATLAS' highly unusual trajectory is "fine-tuned to get unusually close to Jupiter, Mars and Venus," an exceedingly improbable path. Loeb and his colleagues have also posited that the object's large size — roughly 12.4 miles in diameter, according to his calculations — makes it an immensely rare, once-in-only-10,000-years encounter. To neatly summarize his stance on the chance that we're looking at a visitor from an interstellar civilization, Loeb and his colleagues constructed the "Loeb Scale," which ranks the chance of a given object being alien technology on a scale of one to ten, where one is "likely natural," and 10 is "confirmed technology" of "extraterrestrial artificial origin." The scale takes "incorporates multiple observable characteristics, including trajectory anomalies, spectroscopic signatures, geometric properties, and other observable characteristics that could distinguish natural from potentially artificial objects" into account. This week, Loeb gave 3I/ATLAS his "Loeb Scale" rating. "As of now, I give 3I/ATLAS a rank of 6, but note that this rank is time-dependent as it reflects the limited data we have so far," he wrote in his blog post. He also took the opportunity to once again warn that the scientific community shouldn't dismiss the possibility of a first encounter, no matter how far-fetched. "The scientific method allows for all possible questions, which are later answered by collecting data and ruling out possibilities," he wrote. "It is anti-scientific to suppress curiosity-driven questions about anomalies before conclusive data is gathered to explain them." More on the object: Existing NASA Spacecraft Could Intercept the Weird Interstellar Object Cruising Into Our Star System Solve the daily Crossword
Medscape
an hour ago
- Medscape
Meta-Analysis Finds Biologic Switches Effective in Psoriasis
TOPLINE: Interclass biologic switching is effective and safe in patients with psoriasis, though switching from an anti-tumor necrosis factor (anti-TNF)-alpha to an anti-interleukin (IL)-17A treatment was associated with higher risk for adverse events (AEs), according to a meta-analysis. METHODOLOGY: To evaluate the safety and effectiveness of switching treatments after an initial biologic treatment fails, researchers conducted a meta-analysis of 24 randomized clinical trials published through January 25, 2025, which included 12,661 adults with psoriasis who switched from one biologic agent to another within the same class or in a different class. Eight switching categories were analyzed. The primary endpoint was the Psoriasis Area and Severity Index (PASI) 90 score, and secondary endpoints included safety. TAKEAWAY: PASI 90 improved significantly in patients after interclass biologic switching both at week 4 (11 studies; odds ratio [OR], 6.53; 95% CI, 2.58-16.51) and long term (OR, 28.61; 95% CI, 12.89-63.47). All switches were effective in the short term, whereas most switches achieved a PASI 90 response in the long term, except for switches from anti-IL-17A agents to anti-IL-17A/F agents. Long-term, marked improvements were observed when switching from anti-TNF-alpha agents to anti-IL-23p19 agents (OR, 23.72; 95% CI, 4.29-130.98) and from anti-IL-12/23p40 agents to anti-IL-23p19 agents (OR, 19.87; 95% CI, 10.40-37.94). No major safety differences were observed overall, except for increased serious adverse events (AEs) when switching from an anti-TNF-alpha agent to an anti-IL-17A agent (OR, 2.45; 95% CI, 1.25-4.83). Switching from anti-TNF-alpha agents to anti-IL-23p19, anti-IL-17A, or anti-IL-12/23p40 agents was associated with infection rates of 0.62%, 0.54%, and 0.39%, respectively. The highest risk for Candida infection (0.16%) was observed when switching from anti-TNF-alpha agents to anti-IL-17A/F agents. Switching to a different biologic class showed comparable effectiveness and safety with continuing the same agent, with regards to AEs. IN PRACTICE: This systematic review and meta-analysis found that 'interclass biologic switching was effective, and there were no safety differences for most patients,' the study authors wrote. 'Switching to anti-IL-23p19, anti-IL-17A, or anti-IL-12/23p40 agents from anti-TNF-alpha agents posed the greatest risk of infection,' they added, recommending 'vigilance for infections while switching to different biologics.' SOURCE: The study was led by Miao Zhang, MD, Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, and was published online on August 6 in JAMA Dermatology. LIMITATIONS: Limitations included heterogeneity in study designs, potential differences between biologics and batch variability which could have affected effectiveness comparisons after switching, insufficient data for several comparisons. DISCLOSURES: The study was supported by the National Natural Science Foundation of China, the Key Discipline Construction Project of Shanghai's 3-Year Action Plan for Strengthening the Construction of Public Health System, Shanghai Oriental Talent Program for Top-notch Project, CACMS Innovation Fund, Shanghai Healthy Special Project, The Shanghai 2022 Science and Technology Innovation Action Plan Medical Innovation Research Special Project, the Clinical Research Plan of Shanghai Shenkang Hospital Development Center, the High-level Chinese Medicine Key Discipline Construction Project, Evidence-based dermatology base sponsored by State Administration of Traditional Chinese Medicine, and the Shanghai Hospital Development Center Foundation. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
